The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2022 | Exciting ongoing trials in frontline transplant-eligible patients with multiple myeloma
Saad Usmani, MD, MBA, FACP, Memorial Sloan Kettering Cancer Center, New York, NY, gives an overview of ongoing trials evaluating frontline therapies in patients with multiple myeloma who are transplant eligible. Multiple trials are currently comparing triplet versus quadruplet induction therapy followed by post-transplant consolidation and maintenance with daratumumab and lenalidomide versus lenalidomide alone. Dr Usmani notably mentions CARTITUDE-6 (NCT05257083) which compares autologous stem cell transplantation vs CAR-T therapy with ciltacabtagene autoleucel (cilta-cel) following quadruplet induction therapy. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
